Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 32,112 shares at $0.69 ($23K) on 2019-01-25, disclosed to the SEC on 2019-01-29.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.69 | 10,828 | $7K | 32.9% |
| 2 | $0.71 | 15,884 | $11K | 49.7% |
| 3 | $0.73 | 5,400 | $4K | 17.4% |
| Total | $0.71 avg | 32,112 | $23K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |